



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

20 May 2021  
EMA/259161/2021  
Committee for Medicinal Products for Human Use (CHMP)

## Summary of opinion<sup>1</sup> (post authorisation)

---

### Libtayo cemiplimab

On 20 May 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Libtayo. The marketing authorisation holder for this medicinal product is Regeneron Ireland Designated Activity Company (DAC).

The CHMP adopted new indications as follows:<sup>2</sup>

#### Cutaneous Squamous Cell Carcinoma

Libtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.

#### Basal Cell Carcinoma

**Libtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).**

#### Non-Small Cell Lung Cancer

**Libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in  $\geq 50\%$  tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:**

- **locally advanced NSCLC who are not candidates for definitive chemoradiation, or**
- **metastatic NSCLC.**

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report

---

<sup>1</sup> Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

<sup>2</sup> New text as bold



(EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.